Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947739 · ClinicalTrials.gov registry record · Phase 1
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00947739 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 43 participants.
The verdict
NCT00947739, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1. To describe the dose limiting toxicities and adverse event profile of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day. 2. To determine Phase II recommended dose of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day. Secondary: 3. To perform a pharmacokinetic study of orally administered CZ48 in the plasma. 4. To assess responses by RECIST criteria. 5. To follow patients for survival.
Interventions
- DRUG Camptothecin-20-O-Propionate Hydrate (CZ48)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947739
The ClinicalTrials.gov registry entry for NCT00947739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Camptothecin-20-O-Propionate Hydrate (CZ48) is the first listed.
NCT00947739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947739 about?
NCT00947739 is a clinical study titled "Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma". This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1. To describe the dose limiting toxicities and adverse event profile of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day...
What is the current status of trial NCT00947739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2008-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00947739?
The interventions under investigation include: Camptothecin-20-O-Propionate Hydrate (CZ48) (DRUG).
Who is sponsoring clinical trial NCT00947739?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.